微卫星高度不稳定胃癌中PD-1阻断应答与内在耐药的决定因素
该II期试验在晚期MSI-H胃癌患者中给予帕博利珠单抗,并采集连续多区域组织及外周血分析。WES衍生的非同义突变数与抗肿瘤活性及更长PFS相关;应答者治疗中突变架构崩塌更明显,T细胞受体多样性及PD-1+CD8+T细胞增加与持久临床获益相关。
要点
- WES非同义突变数与帕博利珠单抗抗肿瘤活性及PFS延长相关
- 应答者治疗中突变架构崩塌更显著,提示动态肿瘤演化
- T细胞受体多样性与PD-1+CD8+T细胞增加关联持久获益
核心结论
- MSI-H胃癌对帕博利珠单抗存在应答异质性,基线及早期治疗中生物标志物分析有助于识别应答者。
研究设计与样本
- 在晚期MSI-H胃癌患者中开展帕博利珠单抗II期试验,纳入连续多区域组织样本及连续外周血分析。
主要发现
- WES衍生的非同义突变数与抗肿瘤活性相关并与更长PFS相关。
- 应答者治疗中突变架构崩塌更显著,肿瘤演化呈动态变化。
- T细胞受体多样性与帕博利珠单抗更长PFS相关。
- PD-1+CD8+T细胞增加与持久临床获益相关。
临床怎么用
- 可考虑基线及早期治疗中扩展生物标志物分析以识别帕博利珠单抗应答者。
- 内在耐药标志物有助于患者分层并指导新型联合策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sequence alterations in microsatellites and an elevated mutational burden are observed in 20% of gastric cancers and associated with clinical response to anti-PD-1 antibodies. However, 50% of microsatellite instability-high (MSI-H) cancers are intrinsically resistant to PD-1 therapies. We conducted a phase II trial of pembrolizumab in patients with advanced MSI-H gastric cancer and included serial and multi-region tissue samples in addition to serial peripheral blood analyses. The number of whole-exome sequencing (WES)-derived nonsynonymous mutations correlated with antitumor activity and prolonged progression-free survival (PFS). Coupling WES to single-cell RNA sequencing, we identified dynamic tumor evolution with greater on-treatment collapse of mutational architecture in responders. Diverse T-cell receptor repertoire was associated with longer PFS to pembrolizumab. In addition, an increase in PD-1+ CD8+ T cells correlated with durable clinical benefit. Our findings highlight the genomic, immunologic, and clinical outcome heterogeneity within MSI-H gastric cancer and may inform development of strategies to enhance responsiveness. SIGNIFICANCE: This study highlights response heterogeneity within MSI-H gastric cancer treated with pembrolizumab monotherapy and underscores the potential for extended baseline and early on-treatment biomarker analyses to identify responders. The observed markers of intrinsic resistance have implications for patient stratification to inform novel combinations among patients with intrinsically resistant features.See related commentary by Fontana and Smyth, p. 2126.This article is highlighted in the In This Issue feature, p. 2113.
引用
- Kwon M, An M, Klempner SJ, et al. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. Cancer Discov. 2021. PMID: 33846173. doi:10.1158/2159-8290.CD-21-0219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。